MTOR and hepatocellular carcinoma: As PI3 K inhibitor LY294002 has been reported to display its effect in low significance in HCC cells, whereas mTOR inhibitor rapamycin was found to robustly inhibit the activation of mTOR and AKT 42, 43 and was more effective than LY294002 in HCC cells.44